1544280-00-3

Upstream product

• 637-59-2 1-Bromo-3-phenylpropane 
• 6066-82-6 1-hydroxy-pyrrolidine-2,5-dione 
• 143097-60-3 (±)-2-methyl-5-phenylpentanoic acid 

Downstream Products

• 1544279-97-1 (S)-(+)-dimethyl (3-methyl-2-oxo-6-phenylhexyl)phosphonate 
• 1334716-17-4 (S)-(+)-2-methyl-5-phenylpentanoic acid 
• 1431617-37-6 (S)-(+)-ethyl 2-methyl-5-phenylpentanoate 
• 1544280-03-6 (S)-N-((R)-2-hydroxy-1-phenylethyl)-2-methyl-5-phenylpentanamide 
• 1544280-15-0 (-)-(R)-N-((R)-2-hydroxy-1-phenylethyl)-2-methyl-5-phenylpentanamide 
• 1544280-12-7 (S)-2,5-dioxopyrrolidin-1-yl 2-methyl-5-phenylpentanoate 

Relevant academic research and scientific papers

METHODS, SYSTEMS, AND COMPOSITIONS FOR PROMOTING BONE GROWTH

The present invention relates to novel bone compositions for locally delivering a therapeutic agent to the site of a bone defect. Therapeutic agents may promote repair of the bone defect and/or treat conditions or disorders such as pain, inflammation, cancer, and infection. The compositions include calcium phosphate cements and a demineralized bone matrix or a collagen sponge. The compositions are useful for implantation in a patient at the site of a bone defect.

DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS

Disclosed herein are compositions and methods of treating osteroporosis, bone fracture, bone loss, and increasing bone density by administration of compounds of formula (I) or compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier, wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification.

METHODS OF SYNTHESIZING A DIFLUOROLACTAM ANALOG

The present invention relates to processes and intermediates for preparing compounds of formula (IA), wherein R1, R4, R5, R6, and L1 are as defined herein. Compounds of formula (IA) have been found useful as EP4 receptor agonists useful in the treatment of glaucoma, osteoporosis, neuropathic pain, and related disorders.

LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS

Disclosed herein are compounds of formula (I) wherein L1, L2, L3, R1, R4, R5, and R6 are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, osteoporosis, bone fracture, periodontal bone loss, orthopedic implant, alopecia, neuropathic pain, and related disorders. Pharmaceutical compositions and methods of treating conditions or disorders are also described.